From professional translators, enterprises, web pages and freely available translation repositories.
number of data entered
broj unijetih podataka
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
is not
nije
Last Update: 2014-08-15
Usage Frequency: 3
Quality:
the address you have entered is not valid.
adresa koju ste unijeli nije valjana.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
it is not.
jer nije.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
in vivo interaction data is not available.
podaci o interakcijama in vivo nisu dostupni.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
administration is not
rifabutinom neophodno, treba
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
retrieving data from %1 is not supported.
dohvaćanje podataka iz% 1 nije podržano.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
the information you have entered is invalid.
informacije koje ste unjeli nisu valjane.
Last Update: 2016-12-21
Usage Frequency: 1
Quality:
entered column alias "%1" is not a valid identifier.
nevaljana vrsta
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting
the url you entered is not valid, please correct it and try again.
unesena url adresa nije valjana. ispravite ju i pokušajte ponovo.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
the e-mail address you have entered is invalid.
e-mail adresa koju ste naveli nije ispravna.
Last Update: 2017-03-09
Usage Frequency: 1
Quality:
access to standardised data on energy costs is not easy.
pristup standardiziranim podatcima o troškovima energije nije lagan.
Last Update: 2017-04-06
Usage Frequency: 1
Quality:
blanket surveillance of electronic communications data is not acceptable."
sveobuhvatni nadzor podataka elektroničke komunikacije nije prihvatljiv.”
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting
data coming from publicly funded research is not always open;
podacima proizašlim iz javno financiranih istraživanja nije uvijek moguće pristupiti;
Last Update: 2017-04-06
Usage Frequency: 1
Quality:
as only limited data are available the clinical significance is not known.
dostupni samo ograničeni podaci te klinička značajnost nije poznata.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the data you have entered is invalid. please check the information you have given by the marked fields.
podaci koje ste unjeli nisu valjani. molimo pogledajte podatke u označenim poljima.
Last Update: 2017-03-09
Usage Frequency: 1
Quality:
based on data from other cyp3a4 inhibitors, a marked increase is not expected.
s obzirom na podatke o drugim inhibitorima cyp3a4, ne očekuje se značajno povećanje.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
due to the lack of data, coadministration of daklinza and etravirine or nevirapine is not recommended.
zbog nedostatka podataka ne preporučuje se istodobna primjena lijeka daklinza s etravirinom ili nevirapinom.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
based on these preliminary data, the concurrent administration of ipilimumab and vemurafenib is not recommended.
na temelju tih početnih podataka, ne preporučuje se istovremena primjena ipilimumaba i vemurafeniba.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
therefore, in the absence of data, treatment beyond one year is not recommended in these patients.
stoga se u ovih bolesnika, zbog nedostatka podataka, ne preporučuje liječenje u trajanju duljem od godinu dana.
Last Update: 2017-04-26
Usage Frequency: 1
Quality: